Similar articles

• Use of 6-mercaptopurine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: balance.

  Jacobstein DA, Baldassano RN. Jacobstein DA, et al. Inflamm Bowel Dis. 2005 Feb;11(2):203-5. doi: 10.1097/00054725-200502000-00016. Inflamm Bowel Dis. 2005. PMID: 15677916 No abstract available.
• Use of 6-mercapturine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: con.

  Griffiths AM. Griffiths AM. Inflamm Bowel Dis. 2005 Feb;11(2):200-2. doi: 10.1097/00054725-200502000-00015. Inflamm Bowel Dis. 2005. PMID: 15677915 No abstract available.
• Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

  Bouhnik Y, Lémann M, Mary JY, Scemama G, Taï R, Matuchansky C, Modigliani R, Rambaud JC. Bouhnik Y, et al. Lancet. 1996 Jan 27;347(8996):215-9. doi: 10.1016/s0140-6736(96)90402-x. Lancet. 1996. PMID: 8551879
• [Questions and answers on the role of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease].

  Gisbert JP, Gomollón F, Maté J, Pajares JM. Gisbert JP, et al. Gastroenterol Hepatol. 2002 Jun-Jul;25(6):401-15. doi: 10.1016/s0210-5705(02)70275-6. Gastroenterol Hepatol. 2002. PMID: 12069704 Review. Spanish. No abstract available.
• [Immunosuppressive treatment and Crohn's disease].

  Delwaide J, Louis E, Gast P, Belaiche J. Delwaide J, et al. Rev Med Liege. 1991 Jan;46(1):22-8. Rev Med Liege. 1991. PMID: 2011678 Review. French. No abstract available.